← FDA DRUG APPROVALS

FDA ANDA · ANDA207848

PIPERACILLIN AND TAZOBACTAM

piperacillin sodium and tazobactam sodium

Sponsor: MILLA PHARMS

APPLICATION
ANDA207848
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-13
LATEST ACTION
2024-05-01
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 12GM BASE/VIAL, TAZOBACTAM SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 36GM BASE/VIAL, TAZOBACTAM SODIUM EQ 4.5GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-05-01Labeling · Supplement 15 · standardAP
2021-03-04Labeling · Supplement 8 · standardAP
2021-03-04Labeling · Supplement 7 · standardAP
2018-05-11UNKNOWN · Original · standardAP
2017-01-13UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →